Trimi's Pharmacy Partners: How We Ensure Medication Quality
The pharmacy that compounds your medication matters as much as the provider who prescribes it. Here is how Trimi selects and monitors its compounding pharmacy partners to ensure quality, safety, and potency.
When you order compounded semaglutide or tirzepatide from Trimi, the medication is produced by licensed compounding pharmacies that meet rigorous quality standards. Unlike some providers who minimize pharmacy quality to maximize margins, Trimi treats pharmacy partnerships as a cornerstone of patient safety.
Medical Disclaimer
This article describes Trimi's pharmacy quality standards. For specific questions about your medication, contact Trimi support or your healthcare provider.
Our Quality Framework
Pharmacy Partner Requirements
- State licensure: Active pharmacy license in good standing with the state board of pharmacy
- 503A compounding: State-board-licensed 503A community sterile compounding with adherence to all applicable state and federal requirements
- USP compliance: Operations following USP 795, 797, and 800 compounding standards
- Quality testing: Potency, sterility, and endotoxin testing on compounded products
- Ingredient sourcing: Pharmaceutical-grade bulk drug substances with certificates of analysis
- Staff qualifications: Trained pharmacists and technicians with compounding expertise
- Facility standards: Clean rooms, proper ventilation, and environmental monitoring
503A vs. 503B Pharmacies
Compounding pharmacies fall into two federal categories. 503A community sterile compounding pharmacies are licensed by their state board of pharmacy, compound pursuant to individual patient prescriptions, and operate under USP <797> sterile-compounding standards. 503B outsourcing facilities are a separate, larger-scale category that registers with the FDA and operates under cGMP. Trimi partners with state-licensed 503A community sterile compounding pharmacies — VialsRx (Texas State Board of Pharmacy license #35264) and GreenwichRx — that compound patient-specific prescriptions under USP <797> standards.
Testing and Quality Assurance
Every batch of compounded medication undergoes testing before it reaches patients. Potency testing confirms that the medication contains the labeled amount of active ingredient. Sterility testing ensures the medication is free from microbial contamination. Endotoxin testing verifies the absence of bacterial endotoxins that could cause adverse reactions. Visual inspection confirms proper appearance, color, and clarity. And beyond-use-date testing establishes how long the medication remains stable and effective.
Ingredient Sourcing
The quality of a compounded medication begins with its ingredients. Trimi's pharmacy partners source semaglutide and tirzepatide bulk drug substances exclusively from qualified pharmaceutical-grade API suppliers that provide certificates of analysis for each batch, maintain full traceability from synthesis to finished product, and undergo their own quality audits. This chain of quality, from raw ingredient to finished medication to temperature-controlled delivery, ensures that what arrives at your door is safe, pure, and effective.
Ongoing Monitoring
Trimi does not simply vet pharmacies once and walk away. Ongoing monitoring includes regular review of pharmacy inspection reports, patient feedback analysis for quality concerns, periodic quality audits, review of any FDA warning letters or enforcement actions in the compounding industry, and immediate investigation of any reported quality issues.
The Bottom Line
The pharmacy behind your compounded medication is a critical quality factor that many patients overlook. Trimi's pharmacy partnerships are selected and monitored with the same rigor that you would expect from any healthcare institution. Affordable pricing does not require quality compromises when you work with the right pharmacy partners.
Quality Medications at Affordable Prices
Semaglutide $99/mo, tirzepatide $125/mo from licensed, quality-focused pharmacies.
View OptionsMore on trimi
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).